Abemaciclib in Newly Diagnosed Meningioma Patients (NCT05940493)
A Phase 2 Multicenter, Double-blind, Randomized-controlled Study of Abemaciclib (CDK4 and 6 Inhibitor) in Newly Diagnosed RB-proficient Grade 3 Meningioma Participants
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors. Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy. This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.
Who can join: Review the eligibility criteria below.
Location: St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- St. Joseph's Hospital and Medical Center — Phoenix, Arizona
📞 Contact the Study Coordinator
Phone: (602) 406-8605
Email: research@ivybraintumorcenter.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Meningioma
- Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas — Chicago, Illinois
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas — Boston, Massachusetts
- Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma — New York, New York
- DOTATATE PET for Meningioma Radiation Planning — Vancouver, British Columbia
- Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC — New York, New York
- A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma — San Francisco, California
Explore by condition: All Meningioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.